Accessibility helpSkip to navigationSkip to contentSkip to footer

Cookies on FT Sites

We use cookies for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.

Accept & continue
Manage cookies
  • Sign In
  • Subscribe
Open side navigation menuOpen search bar
Financial Times
myFT
  • Home
  • World
    Sections
    • World Home
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • Americas
    • Middle East and North Africa
    Most Read
    • EU turns to US in scramble for Oxford/AstraZeneca vaccine
    • UK-EU trade falls sharply as Brexit disruption starts to bite
    • ‘After a year we’re back to square one’: Milan locked in Covid’s grasp
    • Joe Biden’s $1.9tn stimulus bill clears hurdle in Senate
    • France backs Italy’s decision to block vaccine exports to Australia
  • US
    Sections
    • US Home
    • US Economy
    • US Companies
    • US Politics & Policy
    Most Read
    • EU turns to US in scramble for Oxford/AstraZeneca vaccine
    • High-priced tech stocks sink further into bear market territory
    • White House warns of ‘large number’ of victims in Microsoft hack
    • Joe Biden’s $1.9tn stimulus bill clears hurdle in Senate
    • Fears rise among bond investors as Buffett warns on outlook
  • Companies
    Sections
    • Companies Home
    • Energy
    • Financials
    • Health
    • Industrials
    • Media
    • Professional Services
    • Retail & Consumer
    • Tech Sector
    • Telecoms
    • Transport
    Most Read
    • Lloyds Bank plans to become private landlord
    • Pandemic fuels fast food’s appetite for UK expansion
    • FC Barcelona’s presidential hopefuls vow to restore finances — and keep Messi
    • Bank of America reaps trading windfall during Texas blackouts
    • LSE Group shares suffer biggest daily fall in more than 20 years
  • Tech
  • Markets
    Sections
    • Markets Home
    • Alphaville
    • Markets Data
    • Capital Markets
    • Commodities
    • Currencies
    • Equities
    • Fund Management
    • Trading
    • Moral Money
    • ETF Hub
    Most Read
    • The unravelling of Lex Greensill: a mix of bravado and financial alchemy
    • Fears rise among bond investors as Buffett warns on outlook
    • Emerging markets suffer first outflows since October on rate jump
    • US stocks climb and Treasuries gyrate after bumper jobs report
    • SEC charges AT&T and investor relations employees over calls to analysts
  • Climate
  • Opinion
    Sections
    • Opinion Home
    • Columnists
    • The FT View
    • The Big Read
    • Lex
    • Obituaries
    • Letters
    Most Read
    • Fears rise among bond investors as Buffett warns on outlook
    • This is the electric vehicle bubble. And this is the crash.
    • How gay do you feel?
    • Where regals dare: Harry and Meghan’s TV takeover
    • Ishiguro and the rise of techno-pessimism
  • Work & Careers
    Sections
    • Work & Careers Home
    • Business School Rankings
    • Business Education
    • Entrepreneurship
    • Recruitment
    • Business Books
    • Business Travel
    Most Read
    • FT business books: March edition
    • Should I reveal I have a difficult boss when interviewing for jobs?
    • The scourge of work email is far worse than you think
    • Ideas flow as an orchestra and school team up
    • Negotiation skills prove their real-world worth
  • Life & Arts
    Sections
    • Life & Arts Home
    • Arts
    • Books
    • Food & Drink
    • FT Magazine
    • House & Home
    • Style
    • Travel
    • FT Globetrotter
    Most Read
    • Inside the ‘Covid Triangle’: a catastrophe years in the making | Free to read
    • The CEO whisperer: ‘Every leader needs a fool’
    • How gay do you feel?
    • Travels in my iPhone
    • Where regals dare: Harry and Meghan’s TV takeover
  • How to Spend It
  • Sign In
  • Subscribe
  1. Companies
  2. Health
  • Health Care
  • Pharmaceuticals
MenuSearch
  • Home
  • World
  • US
  • Companies
  • Tech
  • Markets
  • Climate
  • Opinion
  • Work & Careers
  • Life & Arts
  • How to Spend It
Financial Times
  • Sign In
  • Subscribe

Health sector

Add to myFT Digest

Add this topic to your myFT Digest for news straight to your inbox

  • Saturday, 6 March, 2021
    Covid-19 vaccines
    EU turns to US in scramble for AstraZeneca vaccine

    Move is part of bloc’s effort to boost faltering immunisation programme

  • Saturday, 6 March, 2021
    Mental health
    Horatio Clare: ‘There is no cure for being you or me’

    After suffering a breakdown, the acclaimed writer has found hope in new therapies

  • Saturday, 6 March, 2021
    Coronavirus pandemic
    US approves new T-cell test for coronavirus

    Emergency use authorisation could help identify ‘long Covid’ sufferers

  • Friday, 5 March, 2021
    Coronavirus pandemic
    Mystery person with P.1 coronavirus variant in UK found

    Health secretary Matt Hancock praises NHS test and trace for ‘dogged determination’ in tracking individual down

  • Friday, 5 March, 2021
    Covid-19 vaccines
    France backs Italy’s decision to block vaccine exports to Australia

    Canberra urges Brussels to review Rome’s move while also expressing sympathy to EU

  • Friday, 5 March, 2021
    Special ReportFT Health: Future of Antibiotics
    Antibiotic resistance: how to tackle a public health crisis

    Recommendations from two FT roundtables with pharma, government, and NGO experts

  • Thursday, 4 March, 2021
    Covid-19 vaccines
    Germany approves AstraZeneca jab for over-65s

    U-turn could help speed up the country’s sluggish Covid-19 vaccination campaign

  • Thursday, 4 March, 2021
    Covid-19 vaccines
    Italy blocks shipment of Oxford/AstraZeneca vaccines to Australia

    Intervention threatens to increase global tensions over procurement of Covid jabs

  • Thursday, 4 March, 2021
    Coronavirus treatment
    No need for lengthy trials of vaccine modifications, UK regulator says

    Decision makes approval possible in as little as two weeks after final data is received from manufacturers

  • Promoted Content
  • Thursday, 4 March, 2021
    Technology sector
    Covid vaccine passports ‘should not last for ever’, says UK developer

    Netcompany chief says health status apps are only a short-term solution as pandemic eases

  • Wednesday, 3 March, 2021
    Coronavirus pandemic
    Stark link between obesity and Covid deaths revealed

    WHO-backed report concludes that 9 out of 10 fatalities have occurred in countries with high obesity levels

  • Wednesday, 3 March, 2021
    Private equity
    Permira bids for $3.7bn medical device maker LivaNova

    Buyout group’s approach comes as private equity makes a push for healthcare deals amid pandemic

  • Wednesday, 3 March, 2021
    Coronavirus pandemic
    Coronavirus: Biden criticises Texas, Mississippi for ending mask mandates — as it happened
  • Wednesday, 3 March, 2021
    National Health Service
    Campaigners claim Budget fails to address stretched healthcare

    NHS funding set to fall as emergency Covid-19 support is scaled back

  • Wednesday, 3 March, 2021
    IPOs
    Insurer Oscar Health falls in Wall Street debut after $1.4bn IPO

    New York company co-founded by Joshua Kushner was valued at almost $8bn in flotation

  • Wednesday, 3 March, 2021
    Lex
    Lex Letter from New York: private equity’s high nursing home death rates Premium

    Study finds PE management led to 10% increase in short-term mortality of Medicare patients

  • Wednesday, 3 March, 2021
    David Pilling
    Pandemics and the paradox of human progress

    The more we destabilise the planet in the name of advancement, the more pathogens will emerge

  • Tuesday, 2 March, 2021
    Coronavirus pandemic
    Texas lifts mask mandate as US states loosen Covid restrictions

    Actions follow Biden administration warnings against rolling back pandemic rules too quickly

  • Tuesday, 2 March, 2021
    Covid-19 vaccines
    Biden says US will have enough jabs to vaccinate all adults by end of May

    White House announces accelerated timeline after brokering production deal between J&J and Merck

  • Tuesday, 2 March, 2021
    Covid-19 vaccines
    Covid vaccines show few serious side-effects after millions of jabs

    Surveillance of AstraZeneca and Pfizer recipients in UK reports minor complaints but few severe reactions

  • Tuesday, 2 March, 2021
    Recreational drugs
    Microdosing study shows placebo effect of taking psychedelics

    UK research into LSD consumption reveals expectation of improved wellbeing drives transformation

  • Tuesday, 2 March, 2021
    The Big Read
    Redemption shot: von der Leyen begins fightback on EU vaccine rollout

    With Europe facing a possible third wave and public doubts about efficacy, the commission president is under pressure from member states

  • Tuesday, 2 March, 2021
    News in-depthCovid-19 vaccines
    Germany loses Covid crown as vaccine campaign falters

    Country lags far behind UK and US while jab strategy and technology underpinning it draw fierce criticism

  • Tuesday, 2 March, 2021
    Special ReportFT 1000: Europe’s Fastest Growing Companies
    FT 1000: the fifth annual list of Europe’s fastest-growing companies

    Green energy supplier takes top spot and London remains the city with the most high-growth businesses

  • Monday, 1 March, 2021
    Covid-19 vaccines
    France lifts restrictions on Oxford/AstraZeneca jab for over-65s

    New data bring about policy shift as other EU countries likely to abandon age limits

Previous You are on page 1 Next

Topics related to Health & pharmaceuticals

Useful links

Support

View Site TipsHelp CentreContact UsAbout UsAccessibilitymyFT TourCareers

Legal & Privacy

Terms & ConditionsPrivacy PolicyCookiesCopyrightSlavery Statement & Policies

Services

FT LiveShare News Tips SecurelyIndividual SubscriptionsGroup SubscriptionsRepublishingContracts & Tenders
Executive Job SearchAdvertise with the FTFollow the FT on TwitterFT TransactSecondary Schools

Tools

PortfolioToday's Newspaper (ePaper)Alerts HubBusiness School Rankings
Enterprise ToolsNews feedNewslettersCurrency Converter
More from the FT Group
Markets data delayed by at least 15 minutes. © THE FINANCIAL TIMES LTD 2021. FT and ‘Financial Times’ are trademarks of The Financial Times Ltd.
The Financial Times and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice.
Financial Times

International Edition

  • Switch to UK Edition
  • Top sections
  • Home
  • World
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • Americas
    • Middle East and North Africa
  • US
    • US Economy
    • US Companies
    • US Politics & Policy
  • Companies
    • Energy
    • Financials
    • Health
    • Industrials
    • Media
    • Professional Services
    • Retail & Consumer
    • Tech Sector
    • Telecoms
    • Transport
  • Tech
  • Markets
    • Alphaville
    • Markets Data
    • Capital Markets
    • Commodities
    • Currencies
    • Equities
    • Fund Management
    • Trading
    • Moral Money
    • ETF Hub
  • Climate
  • Opinion
    • Columnists
    • The FT View
    • The Big Read
    • Lex
    • Obituaries
    • Letters
  • Work & Careers
    • Business School Rankings
    • Business Education
    • Entrepreneurship
    • Recruitment
    • Business Books
    • Business Travel
  • Life & Arts
    • Arts
    • Books
    • Food & Drink
    • FT Magazine
    • House & Home
    • Style
    • Travel
    • FT Globetrotter
  • Personal Finance
    • Property & Mortgages
    • Investments
    • Pensions
    • Tax
    • Banking & Savings
    • Advice & Comment
    • Next Act
  • How to Spend It
  • Special Reports
  • FT recommends
  • Graphics
  • Lex
  • Alphaville
  • Lunch with the FT
  • FT Globetrotter
  • #techAsia
  • Moral Money
  • FTfm
  • Newsletters
  • Video
  • Podcasts
  • News feed
  • myFT
  • Portfolio
  • Today's Newspaper (ePaper)
  • Crossword
  • Our Apps
  • Help Centre
  • Subscribe
  • Sign In